FHT-1015

FHT-1015 is a selective SMARCA4 (IC50 = 4 nM) and SMARCA2 (IC50 = 5 nM) (also known as BRG1 and BRM) inhibitor. FH-1015 is an allosteric inhibitor that causes conformation change in the BRG1/BRM protein upon interaction with an allosteric site, inhibiting ATPase activity. FH-1015 interferes with tumor cell growth and migration. FH-1015 can be studied in research for uveal melanoma and hematologic cancer[1][2][3][4].

Product Specifications

CAS Number

[2368903-18-6]

UNSPSC

12352005

Target

Epigenetic Reader Domain

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/fht-1015.html

Purity

98.41

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(C1=CN(C=C1)S(C)(=O)=O)N[C@@H](CCSC)C(NC2=NC(C3=CC(C4=CC=NC=C4)=CC=C3)=CS2)=O

Molecular Formula

C25H25N5O4S3

Molecular Weight

555.69

References & Citations

[1]Seedor, R. et al., (2021) . Genetic Landscape and Emerging Therapies in Uveal Melanoma. Cancers, 13 (21), 5503. |[2]Gang Fu, et al., SMARCD1 is a dual regulator of PD-L1 expression and cell proliferation facilitating tumor evasion, Pathology - Research and Practice, Volume 270, 2025, 155975, ISSN 0344-0338. |[3]Reichl, K. D., et al., Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 2023. Expert Opinion on Therapeutic Patents, 34 (3), 159–169.|[4]Centore, R.C. et al. (2023) Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers.